Mitsubishi UFJ Asset Management Co. Ltd. Has $254,000 Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 68.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,196 shares of the biotechnology company’s stock after buying an additional 8,190 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Rocket Pharmaceuticals were worth $254,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of RCKT. Wellington Management Group LLP raised its holdings in Rocket Pharmaceuticals by 22.8% in the 3rd quarter. Wellington Management Group LLP now owns 11,242,144 shares of the biotechnology company’s stock valued at $207,642,000 after buying an additional 2,086,424 shares during the last quarter. Vanguard Group Inc. increased its position in Rocket Pharmaceuticals by 18.8% in the 4th quarter. Vanguard Group Inc. now owns 6,577,595 shares of the biotechnology company’s stock valued at $82,680,000 after acquiring an additional 1,040,655 shares during the period. State Street Corp raised its stake in shares of Rocket Pharmaceuticals by 11.6% during the third quarter. State Street Corp now owns 3,102,022 shares of the biotechnology company’s stock valued at $57,294,000 after acquiring an additional 322,156 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Rocket Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 1,617,866 shares of the biotechnology company’s stock worth $29,888,000 after purchasing an additional 14,256 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Rocket Pharmaceuticals by 15.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 656,090 shares of the biotechnology company’s stock worth $8,247,000 after purchasing an additional 86,276 shares during the last quarter. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Rocket Pharmaceuticals Price Performance

RCKT stock opened at $5.56 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. The company’s 50-day moving average is $9.27 and its 200-day moving average is $12.91. The stock has a market capitalization of $592.86 million, a PE ratio of -2.02 and a beta of 1.00. Rocket Pharmaceuticals, Inc. has a 1 year low of $5.52 and a 1 year high of $26.98.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.06. Equities research analysts expect that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RCKT has been the topic of several recent research reports. BMO Capital Markets assumed coverage on Rocket Pharmaceuticals in a report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 target price on the stock. Chardan Capital reduced their target price on Rocket Pharmaceuticals from $62.00 to $54.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Jefferies Financial Group assumed coverage on shares of Rocket Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $29.00 price target for the company. Wedbush initiated coverage on shares of Rocket Pharmaceuticals in a research note on Monday, December 30th. They issued an “outperform” rating and a $32.00 price objective on the stock. Finally, Scotiabank lifted their target price on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.00.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.